26 May 2017

Inivata, in Collaboration with World- Leading Academic Centers, to Present Promising New Clinical Data on the Utility of the InVision™ ctDNA Platform across Multiple Tumor Types at ASCO 2017 Annual Meeting

 

Collaborative projects with leading cancer research centers highlight progress in development of Inivata’s InVision ctDNA liquid biopsy platform

Research Triangle Park, NC and Cambridge, UK, May 26, 2017 -- Inivata, a global clinical cancer genomics monitoring company employing a revolutionary approach to circulating tumor DNA (‘ctDNA’) analysis to improve personalized healthcare in oncology, today announces that six posters will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held from June 2-6 2017 at McCormick Place, Chicago, Illinois, USA.

 

The posters will present new clinical data from collaborations with prestigious cancer centers on the use of Inivata’s highly sensitive InVision ctDNA liquid biopsy platform in the analysis of multiple tumor types:

 

  • Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA

Inivata and University of Chicago Pritzker School of Medicine

Abstract No.: 4124

Session Title: Gastrointestinal (Noncolorectal) Cancer

Presentation Time: Saturday 3 June, 08:00 – 11:30

Location: Hall A, Poster Board #116

 

  • Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)

Inivata and National Cancer Institute of Canada

Abstract No.: 9024

Session Title: Lung Cancer – Non-Small Cell Metastatic

Presentation Time: Saturday 3 June, 08:00 – 11:30

Location: Hall A, Poster Board #350

 

  • Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib

Inivata and Dana Farber Cancer Institute

Abstract No.: 11529

Session Title: Tumor Biology

Presentation Time: Saturday 3 June, 13:15 – 16:45

Location: Hall A, Poster Board #229

  

  • Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC)

Inivata and Gustave Roussy

Abstract No.: 11540

Session Title: Tumor Biology

Presentation Time: Saturday 3 June, 13:15 – 16:45

Location: Hall A, Poster Board #240

  

  • Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting

Inivata and Gustave Roussy

Abstract No.: 11532

Session Title: Tumor Biology

Presentation Time: Saturday 3 June, 13:15 – 16:45

Location: Hall A, Poster Board #232

  

  • Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer

Inivata and The Institute of Cancer Research

Abstract No.: 1015

Session Title: Breast Cancer – Metastatic

Presentation Time: Sunday 4 June, 08:00 - 11:30, 16:45 – 18:00

Location: Hall A, Poster Board #7

 

The abstracts are now available on the ASCO meeting website, www.asco.org. The data presented will be available both on the ASCO and Inivata websites after the conference.

“We are delighted to present these six high quality abstracts at the ASCO Annual Meeting. These publications, in collaboration with a number of world-renowned cancer research centers, add to the growing body of evidence supporting the potential clinical utility of our InVision platform across a range of tumor types.”

Clive Morris

Chief Medical Officer of Inivata

About Inivata

Inivata, a clinical cancer genomics monitoring company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s InVisionTM ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company’s ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts:

Consilium Strategic Communications - Chris Gardner/Laura Thornton/ Rosie Phillips 

inivata@consilium-comms.com, +44 (0)20 3709 5700

Inivata - Karen Chandler-Smith, karen.chandler-smith@inivata.com, +44 (0)7900 430235


Back to previous page